STAAR Surgical (NASDAQ:STAA) Given Consensus Rating of “Hold” by Analysts

Shares of STAAR Surgical (NASDAQ:STAA) have been given a consensus rating of “Hold” by the nine ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $42.83.

Several analysts have weighed in on STAA shares. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research note on Tuesday, January 7th. Stephens upgraded shares of STAAR Surgical to a “hold” rating in a research report on Monday, December 2nd. Finally, Canaccord Genuity Group reduced their price objective on STAAR Surgical from $31.00 to $28.00 and set a “hold” rating on the stock in a report on Monday, December 9th.

STAAR Surgical Price Performance

Shares of STAA opened at $23.97 on Friday. The company has a market capitalization of $1.18 billion, a PE ratio of 54.48 and a beta of 0.63. STAAR Surgical has a one year low of $21.13 and a one year high of $52.68. The company’s fifty day moving average price is $24.73 and its 200 day moving average price is $30.62.

Insider Buying and Selling

In other news, major shareholder Broadwood Partners, L.P. purchased 23,000 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were acquired at an average price of $24.33 per share, with a total value of $559,590.00. Following the completion of the transaction, the insider now owns 10,848,631 shares of the company’s stock, valued at $263,947,192.23. The trade was a 0.21 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have bought 105,876 shares of company stock worth $2,487,168. Corporate insiders own 1.00% of the company’s stock.

Institutional Investors Weigh In On STAAR Surgical

Large investors have recently bought and sold shares of the stock. Van ECK Associates Corp increased its holdings in shares of STAAR Surgical by 12.7% during the third quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after acquiring an additional 393 shares in the last quarter. Sei Investments Co. lifted its position in shares of STAAR Surgical by 2.7% during the 2nd quarter. Sei Investments Co. now owns 15,087 shares of the medical instruments supplier’s stock worth $718,000 after buying an additional 394 shares in the last quarter. Creative Planning boosted its position in STAAR Surgical by 8.0% in the third quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier’s stock worth $205,000 after purchasing an additional 408 shares during the last quarter. LMR Partners LLP boosted its position in STAAR Surgical by 2.2% in the third quarter. LMR Partners LLP now owns 34,712 shares of the medical instruments supplier’s stock worth $1,290,000 after purchasing an additional 743 shares during the last quarter. Finally, Arcadia Investment Management Corp MI purchased a new stake in shares of STAAR Surgical during the 3rd quarter valued at $37,000. 96.70% of the stock is currently owned by institutional investors and hedge funds.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.